Superior Insurance Advisors publishes broker pay disclosure case file

Superior Insurance Advisors released a research compilation on broker compensation disclosure, ERISA litigation and pharmacy benefit manager pricing. The playbook is aimed at employers and fiduciaries who need to document compensation reviews and plan oversight.

Why it matters: - Employers that sponsor health plans face growing pressure to understand broker compensation, pharmacy pricing and fiduciary duties under ERISA. - The compilation frames compensation disclosure as a plan-sponsor responsibility, not just a broker obligation. - The research also points to a broader wave of litigation over health-plan costs and alleged fiduciary failures.

What happened: - Superior Insurance Advisors published "The Conflicted-Broker Playbook," a research compilation on broker compensation disclosure requirements and health-plan litigation. - The firm says the document is an educational resource for employers, chief financial officers and benefits committees. - The compilation gathers federal statutes, court filings and government reports into one reference. - The release references the Consolidated Appropriations Act of 2021 and ERISA Section 408(b)(2)(B). - The disclosure rule requires brokers and consultants to a group health plan to disclose expected direct and indirect compensation in writing and in advance. - The Department of Labor has said a covered service provider’s failure to make the required disclosure may be treated as a prohibited transaction.

The details: - Paul H. Flowers Jr., founder of Superior Insurance Advisors and author of "The Hidden Healthcare Gold Mine," said many employers do not realize the disclosure duty belongs to them. - Flowers urged plan sponsors to request their broker’s complete written compensation disclosure. - The compilation summarizes ERISA class actions filed on Dec. 23, 2025. - The complaints allege that named brokers acted as functional fiduciaries and received commissions ranging from 22% to 40% of premiums on employee-paid voluntary benefits. - The matters listed include Pimm v. United Airlines, No. 1:25-cv-15581 (N.D. Ill.), naming Mercer. - The matters listed include Braham v. Labcorp, No. 1:25-cv-15583 (N.D. Ill.), naming Willis Towers Watson. - The matters listed include Brewer v. Community Health Systems, No. 1:25-cv-15578 (N.D. Ill.), naming Gallagher. - The matters listed include Fellows v. Universal Services of America, No. 1:25-cv-10659 (S.D.N.Y.), naming Mercer and Lockton. - The allegations are unproven, the named brokers deny them, and the courts have not ruled on the merits. - The compilation also describes ERISA claims brought by plan participants against employers over health-plan costs. - In Stern v. JPMorgan Chase, No. 1:25-cv-02097 (S.D.N.Y.), the court permitted a prohibited-transaction claim to proceed. - Earlier claims in Lewandowski v. Johnson & Johnson, No. 1:24-cv-00671 (D.N.J.), and Navarro v. Wells Fargo, No. 0:24-cv-3043 (D. Minn.), were dismissed for lack of standing. - In Oregon Potato Co. v. Marsh & McLennan Agency, No. 4:25-cv-05139 (E.D. Wash.), the court denied a motion to dismiss and declined to rely on a contract label to determine fiduciary status. - Broker compensation practices were also the subject of a New York regulatory investigation in 2004 and 2005. - Several brokerages later established restitution funds, according to public records and corporate filings. - The compilation cites the Blue Cross Blue Shield antitrust litigation, MDL 2406 in the Northern District of Alabama, which settled for about $5.47 billion without an admission of wrongdoing. - Self-funded employers were among the subscriber class in that settlement. - On pharmacy costs, the compilation cites Federal Trade Commission interim staff reports issued in July 2024 and January 2025. - The FTC reported that the three largest pharmacy benefit managers marked up certain specialty generic drugs and generated more than $7.3 billion above estimated acquisition cost between 2017 and 2022. - The Playbook ends with a checklist that Superior Insurance Advisors describes as a documented review process for plan sponsors. - Flowers said an independent advisor with fully disclosed flat-fee compensation, a pass-through pharmacy contract and a documented selection and monitoring process reflects the prudent process ERISA contemplates. - Superior Insurance Advisors says it uses document and claims analysis, including artificial-intelligence tools, to review plan compensation and contracts for employers. - Superior Insurance Advisors says it is not a party to, and does not represent any party in, any of the referenced matters. - The compilation says the matters are identified by case number for verification and that all allegations are attributed to the court filings. - The compilation says the settlements were resolved without admission of wrongdoing. - The compilation is presented for educational purposes and is not legal advice.

Between the lines: - The release ties together disclosure rules, class actions, antitrust settlements and FTC findings to push employers toward more formal broker oversight. - The framing suggests that fiduciary process, not just vendor selection, is becoming a central risk-management issue for plan sponsors. - By highlighting specific case numbers and public records, the compilation is designed to be a verification tool as much as a policy memo.

What's next: - Superior Insurance Advisors is encouraging plan sponsors to obtain complete compensation disclosures and document broker review procedures. - Employers and benefits committees are likely to face more scrutiny over how they select brokers, monitor fees and assess pharmacy contracts. - The litigation cited in the compilation will continue to test how courts interpret fiduciary status, compensation conflicts and standing in health-plan disputes.